Volume 40 1974/1975

Psycho—pharmacologia

Managing Editors

H. Barry III J. O. Cole M. Hamilton E. Jacobsen R. W. Russell

Editorial Board

H. Barry III, Pittsburgh D. Bovet, Roma J. O. Cole, Boston J. Delay, Paris
J. Elkes, Baltimore M. Hamilton, Leeds H. Isbell, Lexington E. Jacobsen, København
M. E. Jarvik, Los Angeles S. S. Kety, Boston C. Kornetsky, Boston
R. W. Russell, Bedford Park M. Shepherd, London Hannah Steinberg, London
E. Strömgren, Risskov A. Wikler, Lexington

Supporting Editors

M. Adler, Philadelphia N.-E. Andén, Göteborg J. Angst, Zürich J. B. Appel, Columbia, SC
S. Barondes, La Jolla A. M. Barrett, Leeds H. Blaschko, Oxford D. Booth, Birmingham
H. Brill, New York P. Carlton, New Brunswick C. K. Connors, Boston P. B. Dews, Boston
A. DiMascio, Boston E. Domino, Ann Arbor J. C. Eccles, Buffalo
U. S. von Euler, Stockholm A. Fessard, Paris M. Fink, New York
S. Fisher, Boston R. Fog, Roskilde S. Garattini, Milano S. Gershon, New York
S. C. Goldberg, Chevy Chase S. P. Grossman, Chicago L.-M. Gunne, Uppsala
H. Hanson, West Point J. Harvey, Iowa City H. E. Hill, Lexington
R. Hind, Cambridge H. Hippius, München L. E. Hollister, Palo Alto
O. Hornykiewicz, Toronto E. Hosoya, Tokyo R. P. Hullin, Leeds S. Irwin, Portland
J. Jaffe, Chicago W. Janke, Düsseldorf R. Jewett, Atlanta
R. T. Jones, San Francisco M. Jouvet, Lyon C. R. B. Joyce, Basel D. Joyce, Perpignan
M. Katz, Rockville, MD R. Kelleher, Boston K. F. Killam, Davis
G. Klerman, Boston N. S. Kline, Orangeburg M. H. Lader, London I. P. Lapin, Leningrad
L. Lasagna, Rochester V. G. Laties, Rochester A. Latz, Boston
O. Lingjærde, Tromsø R. Lipman, Rockville A. Lubin, San Diego E. Marley, London
W. R. Martin, Lexington J. L. McGaugh, Irvine D. E. McMillan, Chapel Hill
N. Mello, Washington A. F. Mirsky, Boston C. Niemegeers, Beerse S. Norton, Kansas City
D. H. Overstreet, Bedford Park, S. Australia D. Overton, Philadelphia G. Pampiglione, London
P. Pichot, Paris R. W. Pickens, Minneapolis A. Randrup, Roskilde D. Richter, Epsom
K. Rickels, Philadelphia R. Rodnight, London J. M. Rose, Leeds R. T. Rubin, Los Angeles
J. Scheel-Krüger, Roskilde J. Schildkraut, Boston C. Schuster, Chicago
R. Shader, Newton Centre C. Shagass, Philadelphia P. Silverman, Macclesfield, Ches.
F. Sjöqvist, Stockholm J. R. Smythies, Edinburgh F. Sulser, Nashville R. Taber, Bloomfield
J. Tecce, Boston T. Thompson, Minneapolis S. Udenfriend, Nutley, NJ
H. Weil-Malherbe, Washington A. Weissman, Groton, CT T. Yanagita, Kawasaki
E. Zaimis, London O. Zangwill, Cambridge

Springer-Verlag
Berlin Heidelberg New York

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publishers.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Springer-Verlag Berlin Heidelberg New York

Printed in Germany by Wiesbadener Graphische Betriebe GmbH, Wiesbaden

© by Springer-Verlag Berlin Heidelberg 1974/1975

Contents

Adams, R. G.: Pre-sleep Ingestion of Two Hypnotic Drugs and Subsequent Performance 185
Astrada, C. A., see Nasello, A. G., *et al.* 25

Barrett, J. E., Weinberg, E. S.: Effects of Chlordiazepoxide on Schedule-Induced Water and Alcohol Consumption in the Squirrel Monkey 319
Beecham, I. J., Handley, S. L.: Potentiation of Catalepsy Induced by Narcotic Agents during Haffner's Test for Analgesia 157
Begleiter, H., see Ho, A. K. S., *et al.* 101
Benkert, O., Gordon, A., Martschke, D.: The Comparison of Thyrotropin Releasing Hormone, Luteinising Hormone-Releasing Hormone and Placebo in Depressive Patients Using a Double-Blind Cross-Over Technique . . . 191
Bickel, P., see Dittrich, A., *et al.* 351
Bost, J., see Croze, S. 259
Bremer, D. A., see Stern, J. A., *et al.* 171
Brewster, J. M., see Siegel, R. K., *et al.* 211
Buser, P., see Viala, D. 225
Buskirk, R. van, McGaugh, J. L.: Pentylenetetrazol-Induced Retrograde Amnesia and Brain Seizures in Mice 77

Cappell, H., Pliner, P.: Regulation of the Self-Administration of Marihuana by Psychological and Pharmacological Variables 65
Chen, R. C. A., see Ho, A. K. S., *et al.* 101
Chesher, G. B., Jackson, D. M.: The Effect of Withdrawal from Cannabis on Pentylenetetrazol Convulsive Threshold in Mice 129
Clemens, J. A., Smalstig, E. B., Sawyer, B. D.: Antipsychotic Drugs Stimulate Prolactin Release 123
Cox, T., Tye, N.: The Effects of Amphetamine, Imipramine and ICI 58,834 (Vivalan), a Potential Antidepressant, on Unconditioned Behaviour in Rats. 297
Croze, S., Bost, J.: Comportement alimentaire du mouton effets de la nialamide et de la 6-hydroxydopamine 259

Dantzer, R., Roca, M.: Tranquilizing Effects of Diazepam in Pigs Subjected to a Punishment Procedure 235
Davis, J. M., see Rosloff, B. N. 53
Dittrich, A., Bickel, P., Zimmer, D.: Effekte von (–)Δ^9-trans-Tetrahydrocannabinol (Δ^9-THC) auf Psychotizismus-Tests. Eine Untersuchung des Eysenckschen Drogenpostulats über Beziehungen zwischen Halluzinogenwirkung und Psychotizismus 351
Dodes, L. M., see Shader, R. I., *et al.* 17
Dureman, I., Norrman, B.: Clinical and Experimental Comparison of Diazepam, Chlorazepate and Placebo 279

Ebert, M. H., see Lamprecht, F., *et al.* 241
Elsmore, T. F., see Rhodus, D. M., *et al* 147

Fisher, S., see Pillard, R. C., *et al.* 205
Fog, R., see Gerlach, J., *et al.* 341
Fog, R., see Pakkenberg, H. 165
Fram, D. H., see Gillin, J. C., *et al.* 305
Freund, G.: Normal Shuttle Box Avoidance Learning after Chronic Phenobarbital Intoxication in Mice 199

Gerlach, J., Thorsen, K., Fog, R.: Extrapyramidal Reactions and Amine Metabolites in Cerebrospinal Fluid during Haloperidol and Clozapine Treatment of Schizophrenic Patients 341
Gillin, J. C., Fram, D. H., Wyatt, R. J., Henkin, R. I., Snyder, F.: L-Histidine: Failure to Affect the Sleep-Waking Cycle in Man 305
Glick, S. D., see Jerussi, T. P. 329

Gordon, A., see Benkert, O., *et al.* 191
Goudie, A. J., see Taylor, M., *et al.* 249

Handley, S. L., see Beecham, I. J. 157
Harding, T.: The Effect of Lysergic Acid Di-Ethylamide on Serum Creatine Kinase Levels 177
Henkin, R. I., see Gillin, J. C., *et al.* 305
Henriksson, B. G., see Järbe, T. U. C. 1
Hirschhorn, I. D., Rosecrans, J. A.: Studies on the Time Course and the Effect of Cholineric and Adrenergic Receptor Blockers on the Stimulus Effect of Nicotine 108
Ho, A. K. S., Tsai, C. S., Chen, R. C. A., Begleiter, H., Kissin, B.: Experimental Studies on Alcoholism I. Increased in Alcohol Preference by 5,6-Dihydroxytryptamine and Brain Acetylcholine 101

Isaac, W., see Kallman, W. M. 313

Jackson, A. H., see Shader, R. I., *et al.* 17
Jackson, D. M., see Chesher, G. B. 129
Järbe, T. U. C., Henriksson, B. G.: Discriminative Response Control Produced with Hashish, Tetrahydrocannabinols (Δ^8-THC and Δ^9-THC), and Other Drugs 1
Jarvik, M. E., see Siegel, R. K., *et al.* 211
Jerussi, T. P., Glick, S. D.: Apomorphine-Induced Rotation in Normal Rats and Interaction with Unilateral Caudate Lesions 329

Kallmann, W. M., Isaac, W.: The Effects of Age and Illumination on the Dose-Response Curves for Three Stimulants 313
Kissin, B., see Ho, A. K. S., *et al.* 101
Knobloch, L. C., see Sofia, R. D., *et al.* 285
Kopin, I. J., see Lamprecht, F., *et al.* 241
Lamprecht, F., Ebert, M. H., Turek, I., Kopin, I. J.: Serum Dopamine-β-Hydroxylase in Depressed Patients and the Effect of Electroconvulsive Shock Treatment 241

Lester, B. K., see Tharp, K. van, Jr., *et al.* 33

Manning, F. J., see Rhodus, D. M., *et al.* 147
Martschke, D., see Benkert, O., *et al.* 191
McClure, J., see Stern, J. A., *et al.* 171
McGaugh, J. L., see Buskirk, R. van 77
Mc Glothlin, W., see Moskowitz, H. 137
McNair, D. M., see Pillard, R. C., *et al.* 205
Moniuszko-Jakoniuk, J., Wiśniewski, K.: The Activation of the Kining-Forming System and the Effects of Thiopental 269
Mortimore, S., see Taylor, M., *et al.* 249
Moskowitz, H., McGlothlin, W.: Effects of Marihuana on Auditory Signal Detection 137

Nasello, A. G., Astrada, C. A., Ramirez, O. A.: Effects on the Acquisition of Conditioned Avoidance Responses and Seizure Threshold in the Offspring of Amphetamine Treated Gravid Rats 25
Norrman, B., see Dureman, I. 279

Pakkenberg, H., Fog, R.: Short-Term Effect of Perphenazine Enanthate on the Rat Brain 165
Pillard, R. C., McNair, D. M., Fisher, S.: Does Marijuana Enhance Experimentally Induced Anxiety? 205
Pliner, P., see Cappell, H. 65
Ramirez, O. A., see Nasello, A. G., *et al.* 25
Rhodus, D. M., Elsmore, T. F., Manning, F. J.: Morphine and Heroin Effects on Multiple Fixed-Interval Schedule Performance in Rats 147
Roca, M., see Dantzer, R. 235
Rosecrans, J. A., see Hirschhorn, I. D. 108

Rosloff, B. N., Davis, J. M.: Effect of Iprindole on Norepinephrine Turnover and Transport 53
Rundell, O. H., Jr., see Tharp, K. van, Jr., *et al.* 33

Sawyer, B. D., see Clemens, J. A., *et al.* 123
Schyler, D., see Silverstone, T. 335
Shader, R. I., Jackson, A. H., Dodes, L. M.: The Antiaggressive Effects of Lithium in Man 17
Siegel, R. K., Brewster, J. M., Jarvik, M. E.: An Observational Study of Hallucinogen-Induced Behavior in Unrestrained *Macaca mulatta* 211
Silverstone, T., Schyler, D.: The Effect of Cyproheptadine on Hunger, Calorie Intake and Body Weight in Man 335
Smalstig, E. B., see Clemens, J. A., *et al.* 123
Snyder, F., see Gillin, J. C., *et al.* 305
Sofia, R. D., Vassar, H. B., Knobloch, L. C.: Comparative Analgesic Activity of Various Naturally Occurring Cannabinoids in Mice and Rats 285
Stern, J. A., Bremer, D. A., McClure, J.: Analysis of Eye Movements and Blinks during Reading: Effects of Valium 171
Syme, G. J., see Syme, L. A. 91
Syme, L. A., Syme, G. J.: The Role of Sex and Novelty in Determining the Social Response to Lithium Cloride 91

Taylor, M., Goudie, A. J., Mortimore, S., Wheeler, T. J.: Comparison between Behaviours Elicited by High Doses of Amphetamine and Fenfluramine: Implications for the Concept of Stereotypy 249
Tharp, K. van, Jr., Rundell, O. H., Jr., Lester, B. K., Williams, H. L.: Alcohol and Information Processing 33
Thorsen, K., see Gerlach, J., *et al.* 341
Tsai, C. S., see Ho, A. K. S., *et al.* 101
Turek, I., see Lamprecht, F., *et al.* 241
Tye, N., see Cox, T. 297
Vassar, H. B., see Sofia, R. D., *et al.* 285

Viala, D., Buser, P.: Effects of a Decarboxylase Inhibitor on the Dopa and 5-HTP Induced Changes in the Locomotor-Like Discharge Pattern of Rabbit Hind Limb Nerves 225

Weinberg, E. S., see Barrett, J. E. 319
Wheeler, T. J., see Taylor, M., *et al.* 249
Williams, H. L., see Tharp, K. van, Jr., *et al.* 33
Wiśniewski, K., see Moniuszko-Jakoniuk, J. 269
Wyatt, R. J., see Gillin, J. C., *et al.* 305

Zimmer, D., see Dittrich, A., *et al.* 351

Indexed in Current Contents

Subject Index

A
Abreaction 171
Activation 269
Activity 313
Additive factor analysis 33
Adrenergic 109
Age 313
Aggression 17
Alcohol 33, 199, 319
—, preference 101
Amnesia, retrograde 77
Amphetamine 25, 211, 249, 297, 313
Analgesic 285
Antidepressants 53, 297
Antipsychotic drugs 123
Anxiety 205
Anxiolytic effect 279
Apomorphine 329
Attention 137
Auditory signal detection 137
Avoidance 199

B
Brain, acetylcholine level 101
—, seizure activity 77

C
Caffeine 313
Cannabidiol 285
Cannabinol 285
Cannabis 129
Car-driving ability 279
Catecholamines 241
Catalepsy 157
Caudate lesions 329
Chlorazepate 279
Chlordiazepoxide 319
Chlorpromazine 211
Cholinergic 109
—, activities, central 101
Clozapine 341
CNS 269
Computer 171
Concept identification 185
Convulsive threshold 129
Creatinekinase 177
Cyproheptadine 335

D
Depression 241
—, endogenous 191
Diazepam 1, 235, 279
5,6-Dihydroxytryptamine 101
Dimethyltryptamine 211
Discrimination 235
Dopamine 123, 225
—, β-hydroxylase, serum 241
—, hypersensitivity 341
Drinking, schedule-induced 319
Drug discrimination 1, 109
—, transfer 1

E
ECoG 77
EEG 77
Electroconvulsive shock treatment 241
Emotionally unstable character disorders 17
Enzymes 177
Equivalency ratio 147
Eye 171

F
Fenfluramine 249
Food intake 335

H
Hallucinations 211
Hallucinogens 211
Haloperidol 341
Hashish 1
Heroin 147
Hippocampus 25
Histamine 305
L-Histidine 305
Homovanillic acid 341
5-HTP 225
Human subjects 17, 33, 65, 137, 171, 177, 185, 191, 205, 241, 279, 305, 335, 341, 351
Hunger 335
5-Hydroxyindoleacetic acid 341
Hypnotic drugs 185

I
ICI 58, 297
Illumination 313
Imipramine 297
Information processing 33
Inhibitory avoidance 77
Intracerebroventricular injections 259
Iprindole 53

K
Kallikrein 269
Kinins 269

L
Learning 25, 199
Lithium carbonate 17
—, chloride 91
Locomotor activities 225
LSD 177, 211
Luteinizing hormone-releasing hormone 191

M
Marihuana 65, 137, 205
—, crude extract 285
Memory, short term 185
Methylphenidate 313
Metrazol 77
Mice 77, 129, 157, 199, 285
Monkeys 211, 319
Mood 205
Morphine 147, 157

N
Narcolepsy 305
Narcotic analgesics 157
Narcotic-like 285
Nerve cell counts 165
Non-narcotic-like 285
Norepinephrine 53
Novelty 91

O
Oculography 171
Olfactory 235

P
Parkinsonism 341
Pentylenetetrazol 77
Performance tests 185
Perphenazine 165
Phencyclidine 1
Phenobarbitol 199
Photographs 91
Pigs 235
Placebo 171, 279
Pregnancy 25
Pre-sleep ingestion 185
Prolactin 123
Proof-reading 185
Psycho-physiological effects 279
Psychoses 177
—, endogenous 351
Psychoticism 351
Psychotropic drugs 1
Punishment 235

R
Rabbits 225
Rats 1, 25, 53, 91, 101, 109, 147, 165, 249, 269, 297, 285, 313, 329
Reaction time 33
Reading 171
REM sleep 305
Response selection 33
Reticular movements 259
Ro 4-4602 225
Rotation 329
Rumination 259

S
Saccade 171
Sedation 199
Seizure 25
Self-administration 65
Serotonin level 101
Sex 91
Sheep 259
Side effects 279
Sleep 305
Social behavior 91
Stereotypy 249
Strain differences 77
Stress 205
Sympathetic nervous system 241

T
Tardive dyskinesia 341
THC-1 285, 351
Thiopental 269
Thyrotropin releasing hormone 191
Time on task 185
—, of day 185
Titration 65
Tolerance 65, 147

U
Uridine uptake 165

V
Valium 171

W
Weight gain 335
Withdrawal 129

Instructions to Authors

1. Papers will be published in **English, French or German.**

2. Authors should submit **manuscripts together with two copies.** The original illustration material (original drawings etc.) and two copies should be submitted together with the manuscript.

3. The text should be as **clear and concise** as possible. Both form and content of the paper should be carefully checked to exclude the need for correction in proof. A charge will be made for changes introduced after the manuscript has been set in type.

4. **Manuscripts** should be typewritten, double-spaced, on one side of letter size paper and with wider margin on the left. The author should mark in the margin where figures and tables may be inserted. All pages should be numbered consecutively. Tables, footnotes and legends for illustrations should be typed (double-spaced) on separate pages. Use the metric system for text and figures.

5. The **first page** should bear:
the title; the name(s) of the author(s); the name of the laboratory where the work was carried out; a running title of not more than 67 typewriter strokes; footnotes to the title (marked by asterisks).

6. Each paper should be preceded by a brief **abstract** in English concerned with the methods used and with the experimental results which should be presented in such a way that it is possible for the reader to assess their significance. It should be as short as possible and should **not exceed 200 words.**
French and German articles should also have an **English translation of the title.**

7. Immediately following the abstract, some relevant **key words** should be supplied for subject indexing.

8. Articles dealing with **original investigations** should first state the problem concisely and arrange the material under Methods, Results, Discussion, References.

9. **Footnotes** should be kept to a minimum and numbered consecutively throughout the paper. Footnotes referring to the heading of the article are to be marked by asterisks.

10. The **bibliography** should include only work cited in the text. References should be listed alphabetically at the end of the paper as follows: *journal papers*—names and initials of all authors, full title, journal abbreviated in accordance with World Medical Periodicals, volume number, first and last page numbers, year in parentheses; *books*—names of authors, full title, edition, place, publisher, year. *Examples:*

Latz, A., Bain, G. T., Kornetsky, C.: Attenuated effect of chlorpromazine on conditioned avoidance as a function of rapid acquisition. Psychopharmacologia (Berl.) **14**, 23—32 (1960).

Fisher, S., Cole, J. O., Rickels, K., Uhlenhuth, E. H.: Drug set interaction: The effect of expectation on drug response in outpatients. In: Neuropsychopharmacology, Bradley, P. B., Flugle, F., and Hoch, P., eds., vol. 3, pp. 149—156. Amsterdam: Elsevier 1964.

Several publications by the same author or group of authors should be listed in chronological order; those that appear in the same year should be distinguished by the suffixes a, b, c etc. Citations in the text should be given in parentheses, e.g. (Beckman, 1958; Brown, 1963), except when the author's name is part of a sentence, e.g. "Man (1966) reported that . . ." When a paper with more than two authors is cited, only the first need be named, followed by "*et al.*".

11. Figures should be separated from the text and numbered. They should be restricted to a minimum. Descriptions in captions should not be expanded in the text, nor should the same data be given in both graph and table form. Coloured or previously published illustrations are not usually accepted. Original drawings and graphs should be drawn in Indian ink with lines of uniform thickness. Where possible, **figures should be grouped,** bearing in mind maximum display area is 108×177 mm ($4^1/_4'' \times 7''$). In general it should be assumed that the same degree of reduction will apply to all figures in the same paper. Inscriptions should allow for any reduction in scale—a capital letter should be about 1.8 mm high in the final version. If figures have to be redrawn for the block-maker, this may cause considerable delay in publication. Photographs should be sharp, well-contrasted glossy prints at right angles. Authors should mark them with Letraset (Instant Lettering).

INTERACT

Computer Control Systems for Behavioral Research



Here are the most advanced systems available today for Behavioral Research – the **BRS/LVE** INTERACT Computer Control Systems.

They were developed especially for Experimental Psychologists, Psychopharmacologists, Neuropsychologists and other behavioral scientists actively involved in the analysis, control and modification of the behavior of living organisms.

With an INTERACT system it is now possible for you to initiate programs which heretofore had been considered too complex and time consuming for conventional control systems. Almost immediately and without any special computer training, you can begin using this powerful instrument to run experiments that call for the presentation of stimuli, the accumulation of response information, the issuance of control signals to reinforcement devices and the command of appropriate print out devices and recorders.

INTERACT systems are extremely powerful, practical and versatile . . . yet amazingly easy to learn and use.

For more detailed information call or write BRS/LVE today.

BRS/LVE
Division of Tech Serv Inc.

5301 Holland Drive • Beltsville, Maryland 20705
Phone: 301-474-3400
TWX: 710-828-0515

Responsible for advertisements: L. Siegel, D-1000 Berlin 15, Kurfürstendamm 237
Telephone: (030) 8821031, Telex: 01-85411
Springer-Verlag, Berlin Heidelberg New York
Printed in Germany by Wiesbadener Graphische Betriebe GmbH, D-6200 Wiesbaden

© by Springer-Verlag, Berlin Heidelberg 1975